<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802541</url>
  </required_header>
  <id_info>
    <org_study_id>P031217</org_study_id>
    <nct_id>NCT01802541</nct_id>
  </id_info>
  <brief_title>Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism</brief_title>
  <official_title>Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diacylglycerol oil has been shown to lower postprandial and fasting serum triacylglycerol
      levels and reduce body fat. The investigators hypothesize that replacing dietary fat with
      diacylglycerol oil reduces excess body fat in type 2 diabetic patients and that
      diacylglycerol oil has a beneficial effect on cardiovascular risk factors in Chinese type 2
      diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin resistance</measure>
    <time_frame>120 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">127</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>DAG oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAG oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>diacylglycerol oil</intervention_name>
    <arm_group_label>DAG oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>triacylglycerol oil</intervention_name>
    <arm_group_label>TAG oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetic patients, blood sugar levels were stabilized between 7.0Ôºç10.0 mmol/L

          2. Male, aged 40 - 70 years old, Female, aged post-menopausal - 70 years old.

          3. Overweight/obese patients (BMI 25 - 40 kg/m2)

          4. Currently under diet therapy for diabetes mellitus

          5. Understands the procedures and willing to participate in the study

        Exclusion Criteria:

          1. Patients who unwilling to give informed consent

          2. Type 1 diabetic patients

          3. Familial hyperlipemia patients or blood triacylglycerol concentration &gt; 400 mg/dl

          4. Patients with a history of cardiovascular disease and/or arteriosclerotic disease

          5. Patients with a history of cerebrovascular disease

          6. Patients with serious hepatic disease and/or renal disease

          7. Patients with malignancy

          8. Participation in another clinical study within 30 days prior to screening period.

          9. Has a condition the doctor in charge believes would interfere with evaluation of the
             subject, or may put subject at undue risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Duo Li, Ph.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Duo li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>diacylglycerol oil</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

